MHB-036C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase II drugs for Pancreatic Ductal Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the MHB-036C LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MHB-036C overview
MHB-036C is under development for the treatment of solid tumors, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), pancreatic cancer Ductal adenocarcinoma (PDAC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), urothelial carcinoma (UC), ovarian cancer (OC), carcinoma (BC), gastric cancer (GC), castration-resistant prostate cancer (CRPC) and sweat gland carcinoma (SGC), metastatic transitional (urothelial) tract cancer, ureter cancer, bladder cancer, urethral cancer, epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer, metastatic ovarian cancer, triple-negative breast cancer, human epidermal growth factor receptor 2 negative breast cancer, human epidermal growth factor receptor 2 positive breast cancer, metastatic castration-resistant prostate cancer, endometrial cancer. It is being developed based on SuperTopoi ADC platform It is administered through intravenous route. It acts by targeting TROP-2.
For a complete picture of MHB-036C’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.